secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-01-11T23:59:59+00:00
Accession:  0000899923-22-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics expects ~$400M cash on hand, no debt entering 2022
------------------------------------------------------------------

- CEO Paul Diaz presented at 40th Annual J.P. Morgan Health Care Conference on Jan 11, 2022.
- Company expects to start 2022 with approximately $400M in cash, cash equivalents, and marketable securities.
- Preliminary unaudited FY2021 financial data not finalized; adjustments could be material.
- Company reports no debt, highlighting strong liquidity position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/0000899923-22-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/mygn-20220111.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer